Would you consider pembrolizumab for a patient with microsatellite stable stage IV colon cancer with high TMB on liquid biopsy who has progressed on all standard therapies?

The Keynote 158 study demonstrated an objective response rate of 29% in patients with MSS tumors and TMB >=10 mut/MB (Marabelle et al., PMID 32919526). FDA subsequently approved pembrolizumab treatment for patients unresectable or metastatic tumor mutational burden–high (TMB-H; ≥ 10 mutations/megaba...